Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.

N-acetylcysteine antimicrobial peptides bacteriophages carbapenems-resistant nanoparticle natural compounds

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 19 07 2024
accepted: 04 09 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: epublish

Résumé

Carbapenem-resistant (CR) Gram-negative bacteria have become a significant public health problem in the last decade. In recent years, the prevalence of CR bacteria has increased. The resistance to carbapenems could result from different mechanisms such as loss of porin, penicillin-binding protein alteration, carbapenemase, efflux pump, and biofilm community. Additionally, genetic variations like insertion, deletion, mutation, and post-transcriptional modification of corresponding coding genes could decrease the susceptibility of bacteria to carbapenems. In this regard, scientists are looking for new approaches to inhibit CR bacteria. Using bacteriophages, natural products, nanoparticles, disulfiram, N-acetylcysteine, and antimicrobial peptides showed promising inhibitory effects against CR bacteria. Additionally, the mentioned compounds could destroy the biofilm community of CR bacteria. Using them in combination with conventional antibiotics increases the efficacy of antibiotics, decreases their dosage and toxicity, and resensitizes CR bacteria to antibiotics. Therefore, in the present review article, we have discussed different aspects of non-antibiotic approaches for managing and inhibiting the CR bacteria and various methods and procedures used as an alternative for carbapenems against these bacteria.

Identifiants

pubmed: 39355778
doi: 10.3389/fphar.2024.1467086
pii: 1467086
pmc: PMC11442292
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1467086

Informations de copyright

Copyright © 2024 Shariati, Kashi, Chegini and Hosseini.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Aref Shariati (A)

Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran.

Milad Kashi (M)

Student research committee, Arak University of Medical Sciences, Arak, Iran.

Zahra Chegini (Z)

Infectious Disease Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Seyed Mostafa Hosseini (SM)

Infectious Disease Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Classifications MeSH